Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz S, Sendker S, et al. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. Front Immunol. 2022;13:847008 pubmed publisher

Jeffery H, McDowell P, Lutz P, Wawman R, Roberts S, Bagnall C, et al. Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score. PLoS ONE. 2017;12:e0188649 pubmed publisher

Canté Barrett K, Mendes R, Li Y, Vroegindeweij E, Pike Overzet K, Wabeke T, et al. Loss of CD44dim Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus. Front Immunol. 2017;8:32 pubmed publisher

Wolpert F, Happold C, Reifenberger G, Florea A, Deenen R, Roth P, et al. Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells. PLoS ONE. 2015;10:e0139603 pubmed publisher

Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy. 2015;17:621-32 pubmed publisher

Gunturi A, Berg R, Forman J. Preferential survival of CD8 T and NK cells expressing high levels of CD94. J Immunol. 2003;170:1737-45 pubmed